TScan Therapeutics (TCRX) Other Gross PP&E Adjustments (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with -$29.8 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 25.32% to -$29.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.8 million, a 25.32% increase, with the full-year FY2025 number at -$29.8 million, up 25.32% from a year prior.
- Other Gross PP&E Adjustments was -$29.8 million for Q4 2025 at TScan Therapeutics, up from -$59.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $10.4 million in Q4 2021 to a low of -$63.5 million in Q1 2025.
- A 5-year average of -$37.8 million and a median of -$42.2 million in 2023 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 2856.82% in 2021, then crashed 1180.1% in 2023.
- TScan Therapeutics' Other Gross PP&E Adjustments stood at $10.4 million in 2021, then tumbled by 479.41% to -$39.5 million in 2022, then fell by 6.81% to -$42.2 million in 2023, then increased by 5.44% to -$39.9 million in 2024, then grew by 25.32% to -$29.8 million in 2025.
- Per Business Quant, the three most recent readings for TCRX's Other Gross PP&E Adjustments are -$29.8 million (Q4 2025), -$59.9 million (Q3 2025), and -$62.6 million (Q2 2025).